Boosting protection for patients with non-acute cardiovascular disease: a focus on antithrombotic regimen (a consensus expert opinion from the Egyptian Society of Cardiology working group of thrombosis and prevention).
Ahmed BendaryBassem ZarifHala Mahfouz BadranKhaled ShokryHamza KabilPublished in: The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology (2023)
For some stable atherosclerotic CVD patients who are at high risk of cardiovascular events and at low risk for bleeding, a regimen of rivaroxaban and aspirin might be taken into consideration.
Keyphrases
- cardiovascular events
- cardiovascular disease
- atrial fibrillation
- coronary artery disease
- end stage renal disease
- pulmonary embolism
- newly diagnosed
- ejection fraction
- chronic kidney disease
- clinical practice
- type diabetes
- prognostic factors
- cardiac surgery
- liver failure
- drug induced
- acute coronary syndrome
- metabolic syndrome
- percutaneous coronary intervention
- patient reported